Alphatec Hldgs Inc Stock Price, News & Analysis

Alphatec Holdings (Nasdaq: ATEC) reported preliminary, unaudited 2025 results with total revenue of $763.4M–$764.4M (≈25% growth) and surgical revenue of $686.3M–$687.0M (26% growth; volume +24%, revenue per procedure +2%). The company reaffirmed 2025 adjusted EBITDA of $91M and reported cash of ≈$161M and Q4 free cash flow of $6M–$8M. ATEC acquired exclusive U.S. distribution rights for Theradaptive’s OsteoAdapt (next‑gen rhBMP‑2, Phase II). For 2026 the company guides $890M total revenue (+≈17%), surgical revenue ≈$805M, EOS ≈$85M, adjusted EBITDA ≈$130M, and expected free cash flow ≈$20M. Results are preliminary and subject to audit.

Alphatec Holdings (Nasdaq: ATEC) announced the passing of board member Jeffrey P. Rydin at age 59 on November 3, 2025 after a lengthy illness.

Rydin joined ATEC as a Special Advisor in September 2016, was appointed to the Board in June 2017, and was credited with helping transform the company’s sales channel. He had nearly three decades of medical device and healthcare experience, including senior sales roles at Ellipse Technologies, NuVasive, and DePuy Spine. CEO Pat Miles paid tribute to Rydin’s leadership, commitment, and family devotion and offered the company’s condolences to his wife Melissa and sons Spencer and Griffin.

Alphatec Holdings (Nasdaq: ATEC) reported Q3 2025 total revenue of $197 million, up 30% year-over-year, with surgical revenue of $177 million (+31%) and EOS revenue of $20 million (+29%). GAAP net loss was ($29 million) while non-GAAP net income was $4 million. Adjusted EBITDA was $26 million (13% margin) and ending cash was $156 million. ATEC generated $5 million free cash flow in the quarter and was FCF-positive on a trailing twelve-month basis. Full-year 2025 guidance was raised to $760 million revenue and ~$91 million non-GAAP adjusted EBITDA.

Alphatec Holdings (Nasdaq: ATEC) will report Q3 2025 financial results on October 30, 2025 after market close and will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET. Replay will be available on the company's Investor Relations website for 12 months.

Management will present at the North American Spine Society meeting on Nov 14, 2025, the Piper Sandler Healthcare Conference on Dec 2, 2025, and the Stifel MedTech Madness West Coast Tour on Dec 8, 2025. The Board approved inducement grants of 47,106 RSUs to 38 new non‑executive employees, vesting annually over four years and fully vesting on a change of control.

Alphatec Holdings (NASDAQ: ATEC), a spine surgery solutions provider, announced its participation in several upcoming investor conferences in August and September 2025. The company will attend the Needham Virtual MedTech Conference, RBCCM Medical Supplies Symposium, Piper Sandler MedTech Tour, and Wells Fargo Healthcare Conference.

Additionally, ATEC announced the grant of 11,967 restricted stock units (RSUs) to 9 new non-executive employees as employment inducement awards. The RSUs will vest over four years in equal annual installments, with full vesting upon a change of control.

Alphatec Holdings (NASDAQ: ATEC), a spine surgery solutions provider, reported strong Q2 2025 financial results and raised its full-year guidance. The company achieved surgical revenue growth of 29% to $168 million and total revenue growth of 27.5% to $186 million.

Key highlights include a 70% gross margin, 13% adjusted EBITDA margin (expanding 880 basis points year-over-year), and $5 million in free cash flow. The company inflected to non-GAAP net income profitability with $3 million in non-GAAP net income.

ATEC raised its full-year 2025 guidance, now expecting total revenue of $742 million (21% growth) and adjusted EBITDA of $83 million, up from previous expectations of $734 million and $78 million respectively.

Alphatec Holdings (NASDAQ: ATEC), a spine surgery solutions provider, will release its Q2 2025 financial results on July 31, 2025, after market close. The company will host a live webcast at 1:30 PM PT / 4:30 PM ET the same day.

Additionally, ATEC announced the grant of 61,096 restricted stock units (RSUs) to 37 new non-executive employees as employment inducement awards. The RSUs will vest over four years in equal annual installments, with full vesting triggered by a change of control.

ATEC (Alphatec Holdings) reported strong Q1 2025 financial results with significant growth metrics. Total revenue reached $169 million, representing 22% growth, while surgical revenue grew 24%. The company demonstrated solid operational performance with a 69% GAAP gross margin and achieved an Adjusted EBITDA of $11 million with a 6% margin, showing an 840 basis points improvement year-over-year. Key highlights include 17% growth in procedural volume and 18% increase in new surgeon adoption. Based on strong performance, ATEC raised its full-year 2025 guidance, now expecting total revenue of $734 million (20% growth) and adjusted EBITDA of approximately $78 million. The company also successfully refinanced its convertible debt to 2030 maturity and improved free cash use by $55 million compared to Q1 2024.

Alphatec Holdings (ATEC) has announced the commercial launch of its Prone TransPsoas (PTP™) Corpectomy system, expanding its capabilities for complex thoracolumbar spine procedures. The system includes three key components:

1. The Sigma™ LIF Corpectomy Access System for optimized lateral corpectomy exposure

2. The Ascend™ NanoTec™ Vertebral Body Replacement (VBR) System featuring anatomy-driven, expandable design with NanoTec surface treatment

3. The SafeOp™ Neural InformatiX™ System providing real-time monitoring and nerve health assessment

The integrated solution aims to enhance surgical workflow, visualization, and patient outcomes in complex spine surgeries involving tumor, trauma, infection, and deformity cases.